The goal of this clinical trial is to learn whether applying autologous platelet-rich plasma (PRP) to the sternal wound during heart surgery improves wound healing and reduces complications after surgery. The study also aims to evaluate whether PRP can reduce hospital-related outcomes and costs. The main questions this study aims to answer are: Does the use of PRP reduce superficial \& deep sternal wound infections and rate of readmissions? Does PRP improve wound healing after heart surgery? Does PRP reduce the cost of hospitalization and length of ICU stay. Does PRP reduce the requirement of red cell concentrate (RCC) and platelets to less than 4 units each Researchers will compare PRP applied to the sternal wound before closure with standard sternal wound closure alone to determine whether PRP provides additional benefit beyond standard surgical care. Participants were randomly assigned to one of two groups. Participants will: Receive standard sternal wound closure or PRP applied to the sternal wound followed by standard closure Be monitored for wound infections and healing outcomes after surgery Have hospital cost, RCC \& platelet units used, ICU stay, and readmission data recorded during the postoperative period Patients and outcome assessors were blinded to the treatment assignment. Surgeons were aware of the intervention due to the nature of the procedure. This study aims to determine whether adding PRP to standard sternal closure can improve recovery and reduce complications following cardiac surgery.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Superficial & Deep Sternal Wound Infections, Delayed Wound Healing and readmission.
Timeframe: Up to 30 days postoperatively